全文获取类型
收费全文 | 12940篇 |
免费 | 958篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 157篇 |
儿科学 | 361篇 |
妇产科学 | 178篇 |
基础医学 | 1590篇 |
口腔科学 | 283篇 |
临床医学 | 1509篇 |
内科学 | 2884篇 |
皮肤病学 | 227篇 |
神经病学 | 1235篇 |
特种医学 | 627篇 |
外科学 | 2050篇 |
综合类 | 120篇 |
一般理论 | 5篇 |
预防医学 | 907篇 |
眼科学 | 334篇 |
药学 | 745篇 |
中国医学 | 14篇 |
肿瘤学 | 725篇 |
出版年
2023年 | 82篇 |
2022年 | 63篇 |
2021年 | 316篇 |
2020年 | 202篇 |
2019年 | 322篇 |
2018年 | 389篇 |
2017年 | 252篇 |
2016年 | 324篇 |
2015年 | 399篇 |
2014年 | 475篇 |
2013年 | 589篇 |
2012年 | 999篇 |
2011年 | 970篇 |
2010年 | 572篇 |
2009年 | 470篇 |
2008年 | 856篇 |
2007年 | 837篇 |
2006年 | 799篇 |
2005年 | 736篇 |
2004年 | 590篇 |
2003年 | 575篇 |
2002年 | 467篇 |
2001年 | 177篇 |
2000年 | 157篇 |
1999年 | 195篇 |
1998年 | 97篇 |
1997年 | 95篇 |
1996年 | 66篇 |
1995年 | 66篇 |
1994年 | 66篇 |
1993年 | 45篇 |
1992年 | 93篇 |
1991年 | 105篇 |
1990年 | 93篇 |
1989年 | 103篇 |
1988年 | 89篇 |
1987年 | 88篇 |
1986年 | 79篇 |
1985年 | 100篇 |
1984年 | 86篇 |
1983年 | 54篇 |
1982年 | 59篇 |
1981年 | 45篇 |
1980年 | 58篇 |
1979年 | 74篇 |
1978年 | 52篇 |
1976年 | 40篇 |
1975年 | 39篇 |
1972年 | 38篇 |
1971年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
2.
3.
Murat Yücel Erin Oldenhof Serge H. Ahmed David Belin Joel Billieux Henrietta Bowden‐Jones Adrian Carter Samuel R. Chamberlain Luke Clark Jason Connor Mark Daglish Geert Dom Pinhas Dannon Theodora Duka Maria Jose Fernandez‐Serrano Matt Field Ingmar Franken Rita Z. Goldstein Raul Gonzalez Anna E. Goudriaan Jon E. Grant Matthew J. Gullo Robert Hester David C. Hodgins Bernard Le Foll Rico S. C. Lee Anne Lingford‐Hughes Valentina Lorenzetti Scott J. Moeller Marcus R. Munaf Brian Odlaug Marc N. Potenza Rebecca Segrave Zsuzsika Sjoerds Nadia Solowij Wim van den Brink Ruth J. van Holst Valerie Voon Reinout Wiers Leonardo F. Fontenelle Antonio Verdejo‐Garcia 《Addiction (Abingdon, England)》2019,114(6):1095-1109
4.
5.
6.
Mucus plugging constitutes a nutrient‐rich nidus for a bacterial infection that has long been recognized as a potent stimulus for neutrophilic airway inflammation driving progressive lung damage in people with cystic fibrosis (CF). However, mucus plugging and neutrophilic inflammation are already present in many infants and young children with CF even in the absence of detectable bacterial infection. A series of observational studies in young children with CF, as well as investigations in animal models with CF‐like lung disease support the concept that mucus plugging per se can trigger inflammation before the onset of airways infection. Here we review emerging evidence suggesting that activation of the interleukin‐1 (IL‐1) signaling pathway by hypoxic epithelial cell necrosis, leading to the release of IL‐1α in mucus‐obstructed airways, may be an important mechanistic link between mucus plugging and sterile airway inflammation in early CF lung disease. Furthermore, we discuss recent data from preclinical studies demonstrating that treatment with the IL‐1 receptor (IL‐1R) antagonist anakinra has anti‐inflammatory as well as mucus modulating effects in mice with CF‐like lung disease and primary cultures of human CF airway epithelia. Collectively, these studies support an important role of the IL‐1 signaling pathway in sterile neutrophilic inflammation and mucus hypersecretion and suggest inhibition of this pathway as a promising anti‐inflammatory strategy in patients with CF and potentially other muco‐obstructive lung diseases. 相似文献
7.
8.
9.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
10.
Beermann Sandra Jacob Josephine Dudareva Sandra Jansen Klaus Marcus Ulrich Zimmermann Ruth Bremer Viviane 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2020,63(9):1143-1150
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Infektionen in der Schwangerschaft sind weltweit eine der führenden Ursachen für erhöhte Morbidität und... 相似文献